SEC Form 4 · accession 0001104659-19-012421
Neos Therapeutics, Inc. · NEOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard I Eisenstadt
Officer — Chief Financial Officer
Period of report
Mar 1, 2019
Accepted (ET)
Mar 4, 2019 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001467652
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.31 | Mar 1, 2019 | A | 230,276 | A | — | Mar 1, 2029 | Common Stock | 230,276 | 230,276 | D |
Explanation of responses
- F1This stock option will vest in four equal, annual installments beginning on March 1, 2019.